Century Therapeutics
Century Therapeutics is an innovative biotechnology company building an industry-leading, allogeneic, iPSC-derived cell therapy platform for autoimmune diseases and cancer. Their mission is to expand patient access to life-saving cell therapies by developing more effective, tolerable, accessible, and affordable products. The company leverages cutting-edge gene editing, protein engineering, and manufacturing technologies to develop next-generation cell therapies, utilizing their proprietary Allo-Evasion™ technology to avoid host rejection and enable repeat dosing. Century's approach involves using induced pluripotent stem cells (iPSCs) with unlimited replication capacity, engineered with common features to create a platform for generating cancer-fighting NK and T cell products, streamlining manufacturing, and reducing costs. They are actively involved in clinical trials, including CALiPSO-1 and ELiPSE-1, to evaluate the safety and efficacy of their investigational medicines.
Industries
Nr. of Employees
medium (51-250)
Century Therapeutics
Patents
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
US-12269888-B2
View DetailsArtificial cell death polypeptide for chimeric antigen receptor and uses thereof
US-11661459-B2
View Details
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
US-12269888-B2
View DetailsArtificial cell death polypeptide for chimeric antigen receptor and uses thereof
US-11661459-B2
View DetailsProducts
iPSC-derived allogeneic CD19-targeting NK cell product for B cell-mediated autoimmune diseases
An allogeneic, off-the-shelf iPSC-derived natural killer (NK) cell product engineered to target CD19 to deplete pathogenic B cells in autoimmune indications; evaluated in early-phase clinical studies.
iPSC-derived αβ T cell products targeting CD19 and CD19+CD22 for B-cell malignancies
Allogeneic iPSC-derived αβ T cell-based candidates engineered for single or dual antigen targeting (CD19, CD22) intended for treatment of B-cell malignancies.
iPSC-derived γδ T and other non-immune effector cell candidates for hematologic and solid tumors
Preclinical and translational iPSC-derived γδ T cell products and other engineered effector cell types designed for hematologic indications such as multiple myeloma and for selected solid tumor targets.
iPSC-derived cell therapy candidates for solid tumors targeting surface antigens (e.g., Nectin‑4)
Programs focused on generating engineered iPSC-derived immune effectors directed at solid tumor antigens with preclinical development to optimize efficacy and safety.
iPSC-derived allogeneic CD19-targeting NK cell product for B cell-mediated autoimmune diseases
An allogeneic, off-the-shelf iPSC-derived natural killer (NK) cell product engineered to target CD19 to deplete pathogenic B cells in autoimmune indications; evaluated in early-phase clinical studies.
iPSC-derived αβ T cell products targeting CD19 and CD19+CD22 for B-cell malignancies
Allogeneic iPSC-derived αβ T cell-based candidates engineered for single or dual antigen targeting (CD19, CD22) intended for treatment of B-cell malignancies.
iPSC-derived γδ T and other non-immune effector cell candidates for hematologic and solid tumors
Preclinical and translational iPSC-derived γδ T cell products and other engineered effector cell types designed for hematologic indications such as multiple myeloma and for selected solid tumor targets.
iPSC-derived cell therapy candidates for solid tumors targeting surface antigens (e.g., Nectin‑4)
Programs focused on generating engineered iPSC-derived immune effectors directed at solid tumor antigens with preclinical development to optimize efficacy and safety.
Services
Agreements and operational support for investigator-initiated trials and academic collaborations to advance candidate evaluation.
Operational support for trial participants including screening, consent workflows, inpatient monitoring and logistical assistance such as travel and accommodations.
Agreements and operational support for investigator-initiated trials and academic collaborations to advance candidate evaluation.
Operational support for trial participants including screening, consent workflows, inpatient monitoring and logistical assistance such as travel and accommodations.
Expertise Areas
- Allogeneic iPSC-derived cell therapy development
- Gene editing and genome engineering (CRISPR-HDR)
- CAR design and protein engineering
- Differentiation biology and immune effector cell generation
Key Technologies
- Induced pluripotent stem cell (iPSC) platforms
- CRISPR nuclease-mediated homologous directed repair (HDR)
- Chimeric antigen receptor (CAR) engineering
- iPSC differentiation protocols for NK, αβ T and γδ T cells
News & Updates
Press release about upcoming presentations at the EULAR 2025 Congress.
Press release about financial results and business update for Q1 2025, including patient dosing in Phase 1 CALiPSO-1 trial.
Press release about upcoming presentations at the EULAR 2025 Congress.
Press release about financial results and business update for Q1 2025, including patient dosing in Phase 1 CALiPSO-1 trial.